Acteoside improves survival in cecal ligation and puncture-induced septic mice via blocking of high mobility group box 1 release

• Published in: Molecules and cells Vol. 35; no. 4; pp. 348 - 354
• Main Authors: Seo, Eun Sun, Oh, Bo Kang, Pak, Jhang Ho, Yim, Soon-Ho, Gurunathan, Sangilyandi, Kim, Young-Pil, Lee, Kyung Jin
• Format: Journal Article
• Language: English
• Published: Springer Korean Society for Molecular and Cellular Biology 01.04.2013; Korea Society for Molecular and Cellular Biology; 한국분자세포생물학회
• Subjects: Animals; Biochemistry; Biomedical and Life Sciences; Biomedicine; Biotechnology; Cecum - drug effects; Cecum - surgery; Cell Biology; Glucosides - pharmacology; Heme Oxygenase-1 - antagonists & inhibitors; Heme Oxygenase-1 - genetics; Heme Oxygenase-1 - metabolism; HMGB1 Protein - antagonists & inhibitors; HMGB1 Protein - blood; HMGB1 Protein - metabolism; Life Sciences; Ligation - methods; Male; Mice; Mice, Inbred BALB C; Phenols - pharmacology; Research Article; Sepsis - etiology; Sepsis - immunology; Sepsis - mortality; 생물학; acteoside; high-mobility group box 1; nrf2; p38; Raw264.7 cell; heme oxygenase 1; sepsis
• ISSN: 1016-8478; 0219-1032
• DOI: 10.1007/s10059-013-0021-1

Acteoside, an active phenylethanoid glycoside, has been used traditionally as an anti-inflammatory agent. The molecular mechanism by which acteoside reduces inflammation was investigated in lipopolysaccharide (LPS)-induced Raw264.7 cells and in a mouse model of cecal ligation and puncture (CLP)-induced sepsis. In vitro , acteoside inhibits high mobility group box 1 (HMGB1) release and iNOS/NO production and induces heme oxygenase-1 (HO-1) expression in a concentration-dependent manner, while HO-1 siRNA antagonizes the inhibition of HMGB1 and NO. The effect of acteoside is inhibited by the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 and Nfr2 siRNA, indicating that acteoside induces HO-1 via p38 MAPK and NF-E2-related factor 2 (Nrf2). In vivo , acteoside increases survival and decreases serum and lung HMGB1 levels in CLP-induced sepsis. Overall, these results that acteoside reduces HMGB1 release and may be beneficial for the treatment of sepsis.